DE69429821T2 - Farnesyl-derivate und diese enthaltende arzneimittel - Google Patents

Farnesyl-derivate und diese enthaltende arzneimittel

Info

Publication number
DE69429821T2
DE69429821T2 DE69429821T DE69429821T DE69429821T2 DE 69429821 T2 DE69429821 T2 DE 69429821T2 DE 69429821 T DE69429821 T DE 69429821T DE 69429821 T DE69429821 T DE 69429821T DE 69429821 T2 DE69429821 T2 DE 69429821T2
Authority
DE
Germany
Prior art keywords
products containing
medicinal products
farnesyl derivatives
farnesyl
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429821T
Other languages
English (en)
Other versions
DE69429821D1 (de
Inventor
Yoel Kloog
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of DE69429821D1 publication Critical patent/DE69429821D1/de
Application granted granted Critical
Publication of DE69429821T2 publication Critical patent/DE69429821T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69429821T 1993-11-12 1994-11-10 Farnesyl-derivate und diese enthaltende arzneimittel Expired - Lifetime DE69429821T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL10758793A IL107587A (en) 1993-11-12 1993-11-12 Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation
PCT/US1994/013345 WO1995013059A1 (en) 1993-11-12 1994-11-10 Farnesyl derivatives and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
DE69429821D1 DE69429821D1 (de) 2002-03-21
DE69429821T2 true DE69429821T2 (de) 2002-11-28

Family

ID=11065450

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429821T Expired - Lifetime DE69429821T2 (de) 1993-11-12 1994-11-10 Farnesyl-derivate und diese enthaltende arzneimittel

Country Status (7)

Country Link
US (2) US5705528A (de)
EP (1) EP0729354B1 (de)
AU (1) AU1396395A (de)
CA (1) CA2176373C (de)
DE (1) DE69429821T2 (de)
IL (1) IL107587A (de)
WO (1) WO1995013059A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117641A (en) 1996-04-11 2000-09-12 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents and uses related thereto
US6727082B1 (en) 1996-04-11 2004-04-27 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
JP2001513622A (ja) 1996-04-11 2001-09-04 マイトティックス インコーポレーテッド 抗菌剤の同定のためのアッセイおよび試薬、並びにそれらに関連する利用
JP2001513890A (ja) 1997-02-26 2001-09-04 サイレオス コーポレーション リポタンパク質の膜アンカーを標的とする薬剤スクリーニング法
US6303654B1 (en) * 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
AU3743099A (en) * 1998-04-24 1999-11-16 Onyx Pharmaceuticals, Inc. Novel nucleic acids and polypeptides related to a farnesyl-directed cysteine carboxymethyltransferase
AU5497000A (en) * 1999-06-18 2001-01-09 Ramot University Authority For Applied Research And Industrial Development Ltd. Non-malignant disease treatment with ras antagonists
US20050119237A1 (en) * 1999-06-18 2005-06-02 Ramot University Authority For Applied Research & Industrial Development Ltd. Non-malignant disease treatment with Ras antagonists
US20020115696A1 (en) * 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
JP2003506458A (ja) * 1999-08-11 2003-02-18 ジョセフ ピサ， シクロデキストリン誘導体の包接複合体形成の増強
US6372793B1 (en) 1999-08-20 2002-04-16 Florida Agricultural & Mechanical University Method for treatment of a neurological disease characterized by impaired neuromodulator function
US20070054886A1 (en) * 2003-05-23 2007-03-08 Ramot At Tel Aviv University, Ltd. Ras antagonists for treating neurodegenerative disorders
EP1656129A4 (de) * 2003-08-22 2009-03-11 Univ Virginia Blockade von mtor zur prävention einer hormonalen adaptiven antwort
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
CN101039689B (zh) * 2004-06-12 2013-01-30 西格纳姆生物科学公司 用于上皮相关病症的局部组合物和方法
ES2343737T3 (es) * 2004-08-18 2010-08-09 Concordia Pharmaceuticals, Inc. Procedimientos y composiciones de administracion oral de fts.
DE602006017728D1 (de) * 2005-11-28 2010-12-02 Univ Ramot Krebsbehandlung mittels fts und 2-deoxyglucose
WO2007091241A1 (en) * 2006-02-10 2007-08-16 Ramot At Tel Aviv University Ltd. Treatment of ovarian cancer
WO2007116396A1 (en) * 2006-04-11 2007-10-18 Ramot At Tel Aviv University Ltd. Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
WO2007144889A2 (en) * 2006-06-14 2007-12-21 Ramot At Tel Aviv University Ltd. Treatment of neurofibromatosis
CA2672839C (en) 2006-12-19 2012-07-03 Ramot At Tel Aviv University Ltd. Treatment of lung cancer with s-farnesylthiosalicylic acid and analogs thereof
WO2008126094A1 (en) * 2007-04-17 2008-10-23 Ramot At Tel Aviv University Ltd. Treatment of myocarditis using fts
US7897604B2 (en) * 2008-04-07 2011-03-01 Florida Agricultural And Mechanical University Inhibitors of polyisoprenylated methylated protein methyl esterase
US9415026B2 (en) 2009-11-12 2016-08-16 Signum Biosciences, Inc. Use of anti-bacterial agents for the treatment of epithelial-related conditions
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2011051938A1 (en) * 2009-10-26 2011-05-05 Ramot At Tel-Aviv University Ltd. Composition for treatment of thyroid cancer with fts and analogs thereof
US8053207B1 (en) 2011-01-25 2011-11-08 Florida Agrlcultural and Mechanical University Cancer diagnosis by measuring polyisoprenylated methylated protein methyl esterase activity
US8592173B2 (en) 2011-01-25 2013-11-26 Florida Agricultural And Mechanical University Cancer diagnosis by measuring polyisoprenylated methylated protein methyl esterase activity
US9738614B2 (en) 2011-10-07 2017-08-22 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
WO2013052765A1 (en) 2011-10-07 2013-04-11 Pisces Therapeutics Llc Malignant and non-malignant disease treatment with ras antagonists
CN105658651A (zh) * 2012-09-21 2016-06-08 巴兹尔·里格斯 用于治疗炎症相关的病症、疼痛和发热、皮肤病症、癌症及其癌症前期状况的组合物
US9855341B2 (en) 2014-02-19 2018-01-02 University of Pittsburgh—of the Commonwealth System of Higher Education Formulations and carrier systems including farnesylthiosalycylic moities
EP3269365A1 (de) 2016-07-14 2018-01-17 Friedrich-Alexander-Universität Erlangen-Nürnberg Kras-hemmer zur behandlung von krebs
US11857634B2 (en) 2018-04-20 2024-01-02 University of Pittsburgh—of the Commonwealth System of Higher Education Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH568708A5 (de) 1969-04-30 1975-11-14 Hoffmann La Roche
US3879429A (en) 1969-04-30 1975-04-22 Hoffmann La Roche Phenyl derivatives
US3910894A (en) * 1970-05-14 1975-10-07 Du Pont Insect hormone mimics
AU2843371A (en) * 1970-05-22 1972-11-09 Ceskoslovenska Akademie Ved Novel compounds
JPS4924215A (de) 1972-07-03 1974-03-04
DE3113149A1 (de) * 1980-04-07 1982-01-28 Eisai Co Ltd 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaensaeure, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und ihre verwendung als antikrebsmittel und therapeutisches mittel fuer die behandlung von hauterkrankungen
EP0282915B1 (de) * 1987-03-17 1991-04-17 Kuraray Co., Ltd. Verfahren zur Herstellung von Sulfonen
DE3738406A1 (de) * 1987-11-12 1989-05-24 Henkel Kgaa Sebosuppressive topische zubereitungen
CA2076012A1 (en) * 1990-02-14 1991-08-15 Yasuyuki Kato Agent for inhibiting the formation of denatured ldl
US5043268A (en) * 1990-05-04 1991-08-27 The Trustees Of Princeton University Substrates and inhibitors for prenyl cysteine methyltransferase enzymes
CA2050514A1 (en) * 1990-09-14 1992-03-15 Bradley C. Pearce Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia
US5202456A (en) * 1991-04-15 1993-04-13 The President And Fellows Of Harvard College Compounds for inhibition of protein methylation

Also Published As

Publication number Publication date
DE69429821D1 (de) 2002-03-21
USRE39682E1 (en) 2007-06-05
CA2176373A1 (en) 1995-05-18
EP0729354A1 (de) 1996-09-04
JP3757236B2 (ja) 2006-03-22
AU1396395A (en) 1995-05-29
CA2176373C (en) 2009-03-24
EP0729354B1 (de) 2002-02-06
US5705528A (en) 1998-01-06
IL107587A (en) 1998-08-16
WO1995013059A1 (en) 1995-05-18
IL107587A0 (en) 1994-02-27
EP0729354A4 (de) 1996-07-15
JPH09508618A (ja) 1997-09-02

Similar Documents

Publication Publication Date Title
DE69429821T2 (de) Farnesyl-derivate und diese enthaltende arzneimittel
ATE248594T1 (de) Irbesartanhaltiges arzneimittel
DE69328492T2 (de) Fettsäure-derivate und diese enthaltende pharmazeutische präparationen
KR950703566A (ko) 티에노디아제핀 화합물 및 그의 의약 용도[thienodiazepine compound and medicinal use thereof]
IL105221A0 (en) Cyclohexane derivatives and pharmaceutical compositions containing them
BR1100824A (pt) Composto e composição farmacêutica
IL106431A0 (en) Aminediol derivatives and pharmaceutical compositions containing the same
NO305952B1 (no) 1,5-benzodiazepinderivater, anvendelse derav og farmasoeytiske preparater
DE69124721D1 (de) Carbostyrilderivate und diese enthaltende pharmazeutische Zusammensetzungen
HU9502066D0 (en) Pyrrolidine and thiazolidine derivatives, their preparation and drugs containing same
DE69333072D1 (de) Topisch anzuwendendes arzneimittel enthaltend hyaluronsäure und nsaids
DE69417897T2 (de) 2-hydroxypropandiaminderivate und diese enthaltende detergenzzubereitung
DE69320242D1 (de) Medizinische Selbstklebefolie und Arzneimittelzubereitung
EP0498268A3 (en) 5-oxo-l-proline derivatives and pharmaceutical use thereof
DE69732649D1 (de) Heteroarylsulfonamidderivate und diese enthaltende pharmazeutische zubereitungen
DE3685604T2 (de) 1,7-naphthyridinderivate und diese enthaltende arzneimittel.
DE4494713T1 (de) Arylsulfonamidderivate und diese Derivate enthaltende Arzneimittel
DE69427551D1 (de) Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
DE3481125D1 (de) Pheophorbidderivate und diese enthaltende pharmazeutische mittel.
DE59410107D1 (de) Chinoxaline und arzneimittel daraus
DK86492D0 (da) Laegemiddel
DE69622648D1 (de) Benzoxalepin-derivate, deren salze und diese enthaltende arzneimittel
DE69521347T2 (de) Ketonitrilderivate, antibaktrielle mittel und sie enthaltende arzneimittel
DE69509621T2 (de) Diarylheptanoidderivat und diese enthaltende pharmazeutische Zusammensetzung
DE69811253D1 (de) Osteoblastenspezifische mitogene und diese verbindungen enthaltende arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KRAMER - BARSKE - SCHMIDTCHEN, 81245 MUENCHEN